

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	) Examiner: Bunner, Bridget E.
Kevin P. BAKER, et al.	) Art Unit: 1647
Application Serial No. 10/020,063	) Confirmation No: 9309
Filed: December 13, 2001	) Attorney's Docket No. 39780-2830 P1C65
For: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME	) Customer No. 35489 ) )

EXPRESS MAIL LABEL NO. EV 582 628 102 US

DATE MAILED: FEBRUARY 3, 2005

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

## MAIL STOP AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form Supplemental PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

02/10/2005 AWDNDAF1 00000017 081641 10020063

01 FC:1806

180.00 DA

	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):							
			(1) than a c	It is being filed within 3 months of the application filing date and is other continued prosecution application under § 1.53(d) OR				
		ı	(2)	It is being filed within 3 months of entry of a national stage OR				
			(3) merits	It is being filed before the mail date of the first Office Action on the				
			(4) of a req	OR It is being filed before the mailing of a first Office Action after the filing quest for continued examination under § 1.114.				
	filing d stage as action of	late of a n s set forth on the me	ational in §1.4 rits, bu	this statement is being filed after the latest of: (1) three months beyond the application; (2) three months beyond the date of entry of the national 491 in an international application; or (3) the mailing date of a first Office t before the mailing date of the earlier of a final office action under §1.113 e under §1.311, then:				
		a certific	cation a	s specified in §1.97(e) is provided below; or				
	$\boxtimes$			$\underline{0}$ as set forth in §1.17(p) is authorized below, enclosed, or included with other papers filed together with this statement.				
37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of office action under §1.113 or a notice of allowance under §1.311, but before payment of fee, then:								
	A. <sub>'</sub>	a certific	cation a	s specified in §1.97(e) is completed below; and				
	B.			r 37 C.F.R. §1.97(d) requesting consideration of this statement is with; and				
	C.			0 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with other papers filed together with this statement.				
$\boxtimes$	of \$180	0.00 and c	harge a	e Commissioner is hereby authorized to charge the above-referenced fees any additional fees or credit any overpayment associated with this posit Account No. <u>08-1641 (Attorney's Docket No. 39780-2830 P1C65)</u> .				
				Respectfully submitted,				
Dated:	Februar	ry 3, 2005	;	By:				
275 Mi	ddlefiel			& McAULIFFE LLP				

-2-

Telephone: (650) 324-7000 Facsimile: (650) 324-0638

<u> </u>		<del> </del>							Sne	etion			
INFORMATION DISCLOSURE STATEMENT					Attorney's Docket No. Application Serial No.								
TRADEMIN'S			39780-2830 P1C65 10/020,063										
INFORMATION DISCLOSURE STATEMENT					Applicant(s)								
						n P. BAK							
					Filing Date:			up Art Unit:					
	(use se	veral sheet	ts if necessary)		December 13, 2001 1647								
			*	U.S	S. PATENT DOCUMENTS				yr -				
Examiner	Ref.	Date	Document No.		Name	CI	ass	Subclass	Filing Date				
Initials	· No.	ļ			·		(if appropriate)			iate)			
	<u> </u>							l	<u> </u>				
				ORE	IGN PATENT DOCUMENTS			·					
Examiner	Ref.	Date	Document No.		Name	CI	lass	Subclass	Translation				
Initials	No.		·						YES	NO			
			·							<u> </u>			
			* 5 1		OTHER DOCUMENTS	100	* * *	The state of the	2 10				
			(includin	ng au	thor, title, date, pertinent pages, etc	;.)							
Examiner	Ref.	Title											
Initials	No.												
	1.	Hanna, J	.S., et al., "HER-2/neu B	Breat (	Cancer Predictive Testing", Oatholo	ogy Assoc	iates	Medical Lab	oratores - (19	999).			
	2.	Hyman, E	E., et al., "Impact of DNA	A Am	plification on Gene Expression Patt	terns in B	reast	Cancer <sup>1,2</sup> ", C	ancer Resea	rch –			
		<u>62</u> :6240-6	<u>62</u> :6240-6245 (2002)										
1. 1	3.	Orntoft, 1	Orntoft, T.F., et al., "Genome-wide Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pairs of Non-										
·		Invasive	Invasive and Invasive Human Transitional Cell Carcinomas", Molecular & Cellular Proteomics - 1:37-45 (2002)										
	4.	Pollack,	Pollack, J.R., et al., "Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the										
					reast Tumors", <i>PNAS</i> – <u>99(20)</u> :1296								
i.			.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,										
	<del> </del>	<del> </del>											
·													
		1											

EXAMINER: DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2100137 v1